ONCAlert | 2017 NANETS Symposium

Latest NewsMORE >>

According to phase II findings from the MEDIOLA trial presented at the 2017 San Antonio Breast Cancer Symposium, the combination of olaparib and durvalumab demonstrated a disease control rate of 80% for pretreated patients with germline BRCA-mutated, HER2-negative metastatic breast cancer, according to phase II findings from the MEDIOLA trial.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.